archive-com.com » COM » P » PWC.COM

Total: 2203

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Mergers and acquisitions: Global tax services: PwC
    Complete list of PwC territory sites Mergers acquisitions dispositions IPOs Forward looking analysis of the drivers of and barriers to M A activity Click here to see the latest issue Whatever type of transaction you are contemplating an acquisition disposition merger joint venture IPO public to private restructuring or refinancing your tax obligations must be carefully assessed and your cash flows optimised PwC s extensive global network of M A tax specialists can help you structure your transaction to ensure that it is Efficient in the context of commercial and financial considerations Focused on strategic priorities Progressed with the urgency a deal often requires How we can help you PwC has one of the largest network of M A tax specialists in the world with more than 700 deals experienced tax professionals across the globe We can offer you experienced deal structuring and financing advice at all points throughout the deal cycle and aside from our tax specialists our transactions services corporate finance and legal specialists can support you in all aspects of your transaction working as a deals team Our deep experience strong international network and commercial focus allow us to add real financial value to transactions We deliver thorough quantitative analysis rigorous implementation and leading edge structuring techniques We can help you Assess and manage acquisition merger risk Structure acquisitions to optimise net cash flows Prepare businesses for disposal Carry out pre acquisition or pre sale due diligence Ensure that tax compliance requirements are met throughout the deal Global tax About global tax Global Tax code of conduct Indirect taxes eBiz 2015 Global VAT online Research insights International tax services EU direct tax group Latin American Tax Group International Tax Desks Global R D incentives Research insights Mergers acquisitions Tax reporting strategy Tax strategy operations Tax technology Tax

    Original URL path: http://www.pwc.com/gx/en/services/tax/mergers-and-acquisitions.html (2016-02-10)
    Open archived version from archive

  • Change consulting: PwC
    relations Global International PwC Sites Commonly visited PwC sites Global Australia Brazil Canada China Hong Kong France Germany India Italy Japan Mexico Middle East Netherlands Russia Singapore South Africa South Korea Spain Sweden Switzerland United Kingdom United States Complete list of PwC territory sites Change Getting the best from people at every level when there is constant change is the key to sustainable competitive advantage Solid strategies processes and technology alone do not deliver results It takes people to accept adopt drive and sustain the change to realise tangible impact Success in business hinges on strategic agility and the ability to execute We can help if You want to structure your organisation with the right capabilities and leadership to execute the business strategy You want managers to understand manage and own people issues You need to get the right people with the right skills in the right roles at the right time You want to ensure successful change by involving the people impacted and enabling them to drive and sustain the business change You want the organisation s culture to be a competitive advantage You are seeking benchmarks for the efficiency and effectiveness of HR You have to establish the control and coordination required to manage projects and programs successfully achieving the right business results You need to engage and motivate a diverse workforce to focus on the right things and strive for excellence You are seeking effective strategies for people development and growth You want to align risk strategy performance management and reward and ultimately provide a greater likelihood of strategy being executed PwC achieved Vanguard status in the Kennedy Research Vanguard of HR Transformation Consulting Human Capital Strategy Consulting and Change Management Consulting Markets Source Kennedy Research HR Transformation Consulting Market 2013 Human Capital Strategy Consulting Market 2013

    Original URL path: http://www.pwc.com/gx/en/services/advisory/consulting/people-change.html (2016-02-10)
    Open archived version from archive

  • Global metals publications
    Africa South Korea Spain Sweden Switzerland United Kingdom United States Complete list of PwC territory sites Publications Forging ahead Fourth quarter 2015 metals industry mergers and acquisitions analysis February 09 2016 Deal value almost doubled in 2015 compared to the previous year driven mainly by a 31 6 billion third quarter megadeal While activity picks up with a 7 8 percent in volume over the same period Steel market 2025 Quo vadis August 12 2015 Steel market 2015 Steel 2025 Quo vadis which provides an outlook of the steel market to 2025 and highlights the strategies for success in a competitive global environment Metals Deals Forging Ahead 2015 outlook and 2014 review February 23 2015 Welcome to Metals Deals Forging Ahead 2015 outlook and 2014 review PwC s annual analysis of deal activity in the metals industry and our outlook on the prospects for dealmaking in the year ahead We also take a regional look at what is happening in the main markets around the world Making innovation go further in metals How companies could gain by widening their innovation focus March 11 2014 The Metals cut of PwC s Global Innovation Survey shows that it s easy to fall into the trap of associating innovation with only young or fast moving sectors But it s also key to competitive advantage in more mature commodity based industries like metals Forging Ahead Global Metals Deals 2014 outlook and 2013 review February 17 2014 Forging Ahead is PwC s annual analysis of deal activity in the metals industry and PwC s outlook on the prospects for deal making in the year ahead We also take a regional look at what is happening in the main markets around the world Forging Ahead Global Metals Deals 2013 outlook and 2012 review February 03 2013

    Original URL path: http://www.pwc.com/gx/en/industries/metals/publications.html (2016-02-10)
    Open archived version from archive

  • PwC Global Economic Crime 2014 Survey: Economic crime in the pharmaceuticals and life sciences industry
    careers Employer of choice Our history PwC Professional Employability Aspire to lead PwC s series on leadership and gender equality Country job search Explore careers with Strategy Press room Facts and figures Press contacts Analyst relations Global International PwC Sites Commonly visited PwC sites Global Australia Brazil Canada China Hong Kong France Germany India Italy Japan Mexico Middle East Netherlands Russia Singapore South Africa South Korea Spain Sweden Switzerland United Kingdom United States Complete list of PwC territory sites What are the biggest fraud issues in the pharmaceuticals and life sciences sector Here s what we learned from our Global Economic Crime Survey 2014 respondents Bribery and corruption is a major threat At 31 it s the second most commonly reported type of economic crime for pharma and life sciences companies Sector respondents are most concerned about the damage it can do to their corporate reputations Controls are effective but fraud risk assessment is still rare Corporate controls detected 60 of economic crimes in the pharma and life sciences sector and the internal audit function is especially effective But the sector is lagging when it comes to implementing annual fraud risk assessments Pharma and life sciences faces a threat from within 64 of the most serious economic crimes in the pharma and life sciences sector are committed by internal perpetrators compared with just 56 overall Yet pharma and life sciences companies take less action against both internal and external perpetrators So companies may have more work to do when it comes to building a fraud resistant culture Operating in markets with high levels of corruption risk takes extra effort 42 of pharma and life sciences respondents say they ve pursued an opportunity in one during the past 24 months But there are challenges 43 of these respondent say they ve

    Original URL path: http://www.pwc.com/gx/en/services/advisory/consulting/forensics/economic-crime-survey/industry/pharmaceuticals-and-life-sciences.html (2016-02-10)
    Open archived version from archive

  • Pharmaceuticals and life sciences: Managing innovation in pharma: PwC
    Country job search Explore careers with Strategy Press room Facts and figures Press contacts Analyst relations Global International PwC Sites Commonly visited PwC sites Global Australia Brazil Canada China Hong Kong France Germany India Italy Japan Mexico Middle East Netherlands Russia Singapore South Africa South Korea Spain Sweden Switzerland United Kingdom United States Complete list of PwC territory sites Managing innovation in pharma Pharmaceuticals and life sciences Managing innovation in pharma Download Pharmaceuticals and life sciences Managing innovation in pharma Of further interest HRI Medical Technology Innovation Scorecard Breakthrough innovation and growth Contacts Doug Strang Global Pharmaceuticals and Life Sciences Advisory Leader Tel 1 267 330 3045 Kate Moss Partner Global Pharmaceutical and Life Sciences Advisory Services PwC UK Tel 44 20 7804 2268 Innovation in pharmaceuticals has a dramatic impact both on the health and wellness of millions of people and the bottom lines of the companies in the sector Our survey included 76 pharmaceuticals executives across the pharmaceutical value chain situated in 13 countries We found that the Pharma industry invests more of its revenues in innovation than other sectors And the most innovative players are growing faster than their less pioneering competitors though well defined innovation strategies are still far from universal Talent remains a challenge for pharma compared to other industries but executives are putting in place measures to address this They re also looking for inspiration outside their walls with an emphasis on co creation with external partners and even customers Pharma s innovation focus remains on products and business models where they re up there with the top innovators They re less engaged in innovating in other areas such as systems or services Explore the industry trends with Managing innovation in Pharma Pharmaceuticals and life sciences Services Index of services Case studies Publications Pharma

    Original URL path: http://www.pwc.com/gx/en/industries/pharmaceuticals-life-sciences/managing-innovation-in-pharma.html (2016-02-10)
    Open archived version from archive

  • Medtech companies prepare for an innovation makeover: PwC
    s Investor Resource Institute Point of view View CFOdirect About us Alumni Alliances Awards Corporate responsibility Diversity Our global site Press room Video library Careers PwC Open University United States International PwC Sites Commonly visited PwC sites Global Australia Brazil Canada China Hong Kong France Germany India Italy Japan Mexico Middle East Netherlands Russia Singapore South Africa South Korea Spain Sweden Switzerland United Kingdom United States Complete list of PwC territory sites Medical Technology Innovation report Medtech innovation needs redefining in a new health economy that is focused on value and convenience Key findings Create a new medtech innovation engine Business impact Leading practices in medtech innovation Case studies View our Medical Technology Company Innovation Scorecard Explore the data Download the full report and additional related thinking Download Medtech companies prepare for an innovation makeover The medical technology industry was on the forefront of innovation for decades but now return on innovation investment is declining The very notion of medtech innovation needs redefining in a new health economy that is focused on higher expectations for value and convenience Medtech companies must be ready to compete in the new environment or risk being displaced by companies that can show evidence that their innovations create value Some of these companies are non traditional players that are entering healthcare The medtech industry has always viewed innovation as the critical element of success and its importance continues to grow While 64 of executives surveyed by PwC s Health Research Institute HRI view innovation as a competitive necessity today 81 believe it will be in five years But the innovation machine is not working like it used to Download our report to find out why Related materials Innovation Scorecard 2011 Leading drug and device companies are finding the right mix of digital accelerators for a

    Original URL path: http://www.pwc.com/us/en/health-industries/medical-technology-innovation.html (2016-02-10)
    Open archived version from archive

  • Pharmaceutical and Life Sciences Services
    chain to develop a catalogue of services driving the transition from order processor to strategic enabler of the business a partner fully aligned and integrated into the broader business and driven by the evolving requirements of the end consumer the patient Commercial operations In the current environment of poor product pipelines and broader customer bases the traditional sales and marketing model of driving revenue with ever larger sales forces is no longer sustainable Rather organisations will evolve to become more efficient and deliver differentiated effective messages tailored the specific needs of diverse customer segments including patients insurers government and physicians and the changes on product mix PwC can work with you in targeting sales and marketing resources accordingly to the customer needs and the relevant regulations compliance avoiding components that are not helping to maximise the return on invesment improving the division of roles between the headquarters and local maketing companies with redefinition of planning and communication systems that work effectively between global regional and marketing affiliates To read more Pharma 2020 Marketing the future Corporate and financial strategy The Pharmaceutical and Life Sciences industries are at a pivotal point in their evolution Companies and stakeholders are looking for new sustainable business models for the longer term Strategic options include vertical integration versus virtual company generic versus innovative product manufacturer traditional medicines versus biologics makers of medicines versus provider of health care packages These companies are addressing important questions about existing and future revenue generation and how to align operational and financial tactics to enable their chosen corporate strategy We are working with our clients to explore strategic options and begin the process today of restructuring their business for tomorrow We help to identify those areas with the most realistic potential and devise and review pragmatic business plans that maximise value We know the difficult decisions and trade offs that executives face when managing their businesses allocating resources or contemplating deals We know the traps of large and small company cultures Mergers acquisitions and licensing are vital enablers to corporate strategy Most companies will use some form of equity or debt finance to fund future plans Life Science companies often use private equity or an initial public offering IPO Whatever the new venture buying at the price integrating the different elements and ensuring tax efficiencies through out is key to ensure maximum value We help to develop a corporate finance strategy which will appropriately raise and structure the finance needed to support operational changes and the future strategy of the company Informational technology Technology is an important enabler of business transformation In the Pharmaceutical and Life Sciences industry new technologies will enable greater understanding of disease reduce costs in R D manufacturing and the supply chain Technology will also encourage closer relationships with regulators payers providers and patients through a more integrated approach to product development and marketing and health provision through greater transparency and sharing of information across companies and with third parties including industry regulators and potentially patients

    Original URL path: http://www.pwc.com/gx/en/industries/pharmaceuticals-life-sciences/services.html (2016-02-10)
    Open archived version from archive

  • US healthcare M&A insights: PwC
    for Technology and Innovation Financial Services Institute Technology Institute Health Research Institute Center for Board Governance PwC s Investor Resource Institute Point of view View CFOdirect About us Alumni Alliances Awards Corporate responsibility Diversity Our global site Press room Video library Careers PwC Open University United States International PwC Sites Commonly visited PwC sites Global Australia Brazil Canada China Hong Kong France Germany India Italy Japan Mexico Middle East Netherlands Russia Singapore South Africa South Korea Spain Sweden Switzerland United Kingdom United States Complete list of PwC territory sites US Health Services Deals Insights Q3 2015 update November 2015 At a glance Q3 2015 presented continued increases in deal volume across the vast majority of sectors when compared to Q2 2015 Similar to the trend in Q2 the Managed Care sector s deal activity continued as the most significant in terms of impact Download US Health Services Deals Insights Q3 2015 update Create custom report Download chart pack Download the iBook for your iPad Further reading US Health Services Deals Insights Q2 2015 US Health Services Deals Insights Q1 2015 US Health Services Deals Insights 2014 and 2015 outlook US Health Services Deals Insights Q3 2014 US Health Services Deals Insights Q2 2014 US Health Services Deals Insights Q1 2014 US Health Services Deals Insights 2013 in review and 2014 outlook US Health Services Deals Insights Q3 2013 Health Industries Health Services Accountable care Big Data Business model transformation Consumerism Financial management Operational agility Regulatory risk compliance Pharmaceuticals Life Sciences Accountable care Big Data Business model transformation Consumerism Financial management Operational agility Regulatory risk compliance New Entrants Healthcare New Entrants and Innovators New Health Economy Library Featured thinking HRI regulatory center Pharmaceutical and Life Science Accounting Alerts Contact Us Have a question Request by Media Submit RFP About PwC Health

    Original URL path: http://www.pwc.com/us/en/healthcare/publications/healthcare-m-a-insights.html (2016-02-10)
    Open archived version from archive



  •